PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11465930-4	2001	In addition, the first systematic review in the field of ALS/MND from the Cochrane collaboration concerns riluzole treatment and this meta-analysis is also described.	Riluzole	106-114	superoxide dismutase 1	Homo sapiens	57-60	
16909020-6	2005	Moreover, the therapeutic efficacy of riluzole, the only drug proven to slow disease progression in ALS, is most likely related to its anti-excitotoxic properties.	Riluzole	38-46	superoxide dismutase 1	Homo sapiens	100-103	
31352711-6	2019	The same experiments were repeated using SH-SY5Y cells carrying the familial ALS-related G93A-SOD1 mutation and constitutively expressing two-fold increased whole-cell ROS levels with respect to wild-type cells: riluzole was ineffective in this paradigm.	Riluzole	212-220	superoxide dismutase 1	Homo sapiens	94-98	
11018250-12	2000	Comparison between patients treated or not with riluzole did not display any modification of the plasma TBARS concentration, but we observed a slight decrease of erythrocyte SOD activity in treated patients (treated=705+/-113 U/g Hb; not treated=725+/-118 U/g Hb), suggesting a possible activity of riluzole on the oxygenated free radical production.	Riluzole	48-56	superoxide dismutase 1	Homo sapiens	174-177	
8959996-0	1996	A confirmatory dose-ranging study of riluzole in ALS.	Riluzole	37-45	superoxide dismutase 1	Homo sapiens	49-52	
8959996-3	1996	The anti-excitotoxic drug riluzole (100 mg/day) has been shown to decrease mortality and muscular deterioration in ALS patients.	Riluzole	26-34	superoxide dismutase 1	Homo sapiens	115-118	
8959996-12	1996	This study confirms the therapeutic effect of riluzole in a large representative ALS sample, over an 18-month period.	Riluzole	46-54	superoxide dismutase 1	Homo sapiens	81-84	
8959996-13	1996	Riluzole is well tolerated and decreases the risk of death or tracheostomy in ALS patients.	Riluzole	0-8	superoxide dismutase 1	Homo sapiens	78-81	
35326229-0	2022	Combined Treatment with Bojungikgi-Tang and Riluzole Regulates Muscle Metabolism and Dysfunction in the hSOD1G93A Mouse Model.	Riluzole	44-52	superoxide dismutase 1	Homo sapiens	104-109	
35052677-11	2022	Co-administration of BJIGT and RZ did not cause liver damage or toxicity but rather restored liver function in hSOD1G93A mice.	Riluzole	31-33	superoxide dismutase 1	Homo sapiens	111-116	
22169158-1	2012	BACKGROUND: Although amyotrophic lateral sclerosis (ALS) is a relentlessly progressive disorder, early diagnosis allows a prompt start with the specific drug riluzole and an accurate palliative care planning.	Riluzole	158-166	superoxide dismutase 1	Homo sapiens	52-55	
31118868-4	2019	Pharmacological approved treatments for ALS are still limited and include riluzole and edaravone which improve survival over time.	Riluzole	74-82	superoxide dismutase 1	Homo sapiens	40-43	
25245510-4	2014	One drug, riluzole, which possesses anti-glutamatergic properties, is approved as neuroprotective for ALS.	Riluzole	10-18	superoxide dismutase 1	Homo sapiens	102-105	
24038380-8	2013	Only 1 compound, riluzole, is approved by the US Food and Drug Administration for ALS; several therapies are in clinical trials, including 2 mesenchymal stem cell trials.	Riluzole	17-25	superoxide dismutase 1	Homo sapiens	82-85	
28872909-5	2017	The current status of treatment for ALS includes one drug riluzole that slows progression modestly, and another drug edaravone that was recently approved by FDA to slow ALS progression.	Riluzole	58-66	superoxide dismutase 1	Homo sapiens	36-39	
28060747-4	2017	In the motor neuron-like cell line (NSC34) with the human mutant G93A superoxide dismutase 1 gene (mSOD1-G93A), 25-hydroxycholesterol induced motor neuronal death/ apoptosis via glycogen synthase kinase-3beta and liver X receptor pathways; riluzole treatment attenuated these effects.	Riluzole	240-248	superoxide dismutase 1	Homo sapiens	70-92	
26106294-6	2015	We further find that co-application of ACM-SOD1(G93A) with blockers of Nav channels (spermidine, mexiletine, or riluzole) or anti-oxidants (Trolox, esculetin, or tiron) effectively prevent c-Abl activation and motoneuron death.	Riluzole	112-120	superoxide dismutase 1	Homo sapiens	43-47	
25720096-8	2015	Riluzole is the only drug approved by the Food and Drug Administration and recommended by the National Institute for Clinical Excellence so far proven to be successful against ALS and may prevent progression and extend life for a few months or so.	Riluzole	0-8	superoxide dismutase 1	Homo sapiens	176-179	
26785244-8	2014	Combination treatment with Immunocal( ) and the anti-glutamatergic compound, riluzole, delayed disease onset and extended survival in hSOD1(G93A) mice.	Riluzole	77-85	superoxide dismutase 1	Homo sapiens	134-138	
23864030-4	2013	Because riluzole, the only Food and Drug Administration (FDA)-approved treatment, prolongs the ALS patient"s life by only 3 months, new therapeutic agents are urgently needed.	Riluzole	8-16	superoxide dismutase 1	Homo sapiens	95-98	
21796043-8	2011	Drug therapy for ALS is currently limited to riluzole; however, patients may be treated with a number of nonpharmacologic methods on the basis of their symptoms.	Riluzole	45-53	superoxide dismutase 1	Homo sapiens	17-20	
20942785-3	2010	The only drug that is available to treat ALS is riluzole, which extends survival by just 2-3 months.	Riluzole	48-56	superoxide dismutase 1	Homo sapiens	41-44	
19966906-2	2009	Currently, the management of ALS is essentially symptoms-based, and riluzole, an antiglutamatergic agent, is the only drug for the treatment of ALS approved by the food and drug administration.	Riluzole	68-76	superoxide dismutase 1	Homo sapiens	144-147	
19966906-7	2009	CONCLUSIONS: Riluzole is the only compound that demonstrated a beneficial effect on ALS patients, but with only modest increase in survival.	Riluzole	13-21	superoxide dismutase 1	Homo sapiens	84-87